Does Levetiracetam and Carbamazepine Impact the Autonomic Activity of Children With Self-limiting Focal Epilepsy?

NCT ID: NCT06138847

Last Updated: 2023-11-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

119 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-01-01

Study Completion Date

2023-12-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this cross-sectional study is to learn about autonomic cardiac profile changes in children with self-limiting focal epilepsy using levetiracetam and carbamazepine in children with self-limiting focal epilepsy syndrome. The main questions is it aims to answer are:

1. Are heart rate variability and autonomic tone different among healthy controls and children with epilepsy?
2. Does Levetiracetam and carbamazepine affect autonomic tone differently among children with self-limiting focal epilepsy?

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Seventy-eight children with self-limiting focal epilepsy syndrome were enrolled in the study and were divided into two groups. Group I consisted of children with epilepsy who were only taking one type of ASM, either levetiracetam or carbamazepine. They were further subdivided into group Ia, which included patients receiving levetiracetam, and group Ib, which included patients receiving carbamazepine. Group II comprised forty-one age and sex-matched healthy children as a control group.

The pediatric neurologist utilized the clinical definition criteria of the International League Against Epilepsy to diagnose all children with self-limiting focal epilepsy syndrome.

The demographics, clinical data, neuroimaging findings, interictal scalp EEG results, and outcomes of patients' medical records were examined retrospectively. Utilizing the 10-20 system, gold cup electrodes (accompanied by conductive paste and collodium) were placed and used to acquire scalp recordings. Polygraphic derivations generally include an ECG channel, standard EEG recordings, plus an optional EMG channel.

All subjects had echocardiographic (ECHO) testing using M-mode, 2-dimensional, color, pulse, and continuous wave Doppler echocardiograms with a GE Vivid S6. A standard ambulatory electrocardiography (ECG) recording system (Cardioline Click Holter HRV Package System, version 1.4.1 Biomedical Systems, Italy) was used. All of the patients were examined during an at least 24- hour seizure-free period, and none of the patients reported seizures during the recording period and encouraged to perform their normal daily activities. Artifacts and ectopic complexes were excluded. Heart rate variability parameters used for the time domain analysis were the mean and the highest and lowest heart rates. Time domain analysis included the following: standard deviation (SD) of all normal RR intervals (SDNN, ms), SD of the average normal sinus intervals between successive heartbeats (RR intervals) for all 5 min segments of the entire recording (SDANN, ms), the root mean squares successive differences RR intervals (RMSSD, ms), the proportion of the adjacent RR intervals that differ by more than 50 ms in the 24- hour recording (pNN50, measured in percentage). While the RMSSD and pNN50 reflect vagally mediated (i.e., parasympathetic) HRV, the SDNN represents the parasympathetic and sympathetic components of the autonomic nervous system.

The rSUDEP-7 inventory was used to assess group I risk for SUDEP. The SUDEP-7 was found to be associated with a biomarker of vagus-mediated HRV(RMSSD)\[25\]. The revised SUDEP-7 Risk Inventory incorporates seven validated risk factors (Table 1). Since our study cohort consisted of the pediatric age group and the study design was based on patients receiving monotherapy, none of group 1 received points from the 5th and 6th items of the risk factor list.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Epilepsy; Syndrome, Seizures of Localized Onset

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group I

Group I consisted of children with epilepsy who were only taking one type of ASMs, either levetiracetam or carbamazepine

electroencephalogram

Intervention Type DIAGNOSTIC_TEST

Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages

Group II

Group II comprised forty-one age and sex-matched healthy children as a control group.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

electroencephalogram

Polygraphic derivations generally include an ECG channel, which is standard on EEG recordings, plus an optional EMG channel. Subsequently, the signal was recorded at 512 Hz and inspected using the standard bipolar and referential montages

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Based on the ILAE classification, all children with epilepsy are categorized as self-limiting focal epilepsy syndromes.

Exclusion Criteria

* had signs of organic heart disease
* had other conditions that could influence the cardiovascular and autonomic nervous systems (such as systemic lupus erythematosus, and endocrine-metabolic abnormalities)
* use regular medications that have an impact on the cardiovascular and autonomic nervous systems
Minimum Eligible Age

5 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

İpek Dokurel

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

İpek Dokurel

İpek Dokurel Çetin,MD

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Muhlike Guler, MD

Role: STUDY_DIRECTOR

Balikesir Ataturk City Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Balıkesir University Medical Faculty

Merkez, Balikesi̇r, Turkey (Türkiye)

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Turkey (Türkiye)

References

Explore related publications, articles, or registry entries linked to this study.

Hennessy MJ, Tighe MG, Binnie CD, Nashef L. Sudden withdrawal of carbamazepine increases cardiac sympathetic activity in sleep. Neurology. 2001 Nov 13;57(9):1650-4. doi: 10.1212/wnl.57.9.1650.

Reference Type BACKGROUND
PMID: 11706106 (View on PubMed)

Mukherjee S, Tripathi M, Chandra PS, Yadav R, Choudhary N, Sagar R, Bhore R, Pandey RM, Deepak KK. Cardiovascular autonomic functions in well-controlled and intractable partial epilepsies. Epilepsy Res. 2009 Aug;85(2-3):261-9. doi: 10.1016/j.eplepsyres.2009.03.021. Epub 2009 May 5.

Reference Type BACKGROUND
PMID: 19409754 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

levcbzepilepsy

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.